Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records by Nishida, Yayoi et al.
ORIGINAL INVESTIGATION Open Access
Effect of candesartan monotherapy on lipid
metabolism in patients with hypertension:
a retrospective longitudinal survey using data
from electronic medical records
Yayoi Nishida
1,2†, Yasuo Takahashi
1,2†, Tomohiro Nakayama
3†, Masayoshi Soma
4†, Noboru Kitamura
5†,
Satoshi Asai
1,2*†
Abstract
Background: Studies focusing on the add-on effects of angiotensin II type 1 receptor blockers (ARBs) other than
their antihypertensive effect are receiving attention. However, the effects of prolonged administration of ARBs on
lipid metabolism in clinical cases are unclear. Our aims were to survey the changes in plasma lipid profile in
patients with hypertension over a one-year period, and to examine the correlations between these values and the
time after the start of ARB monotherapy with candesartan.
Methods: We carried out candesartan monotherapy in patients with mild to moderate hypertension and
examined the longitudinal changes in plasma lipid profile. Data from 405 patients for triglyceride (TG), 440 for total
cholesterol (TC), 313 for high density lipoprotein cholesterol (HDL-C) and 304 for low density lipoprotein
cholesterol (LDL-C) were obtained from the electronic medical records (EMRs) in the Clinical Data Warehouse
(CDW) of Nihon University School of Medicine (NUSM). The inverse probability of treatment weighting (IPTW)
method (calculated from the inverse of the propensity score) was used to balance the covariates and reduce bias
in each treatment duration. Linear mixed effects models were used to analyse the relationship between these
longitudinal data of blood examinations and covariates of patient sex, age, diagnosis of diabetes mellitus (DM) and
duration of candesartan monotherapy.
Results: Plasma HDL-C level was associated with sex, duration of treatment, and interaction of sex and treatment
duration, but not with age or diagnosis of DM. HDL-C level was significantly decreased during the 6~9 months
period (p = 0.0218) compared with baseline. TG and TC levels were associated with sex, but not with age,
diagnosis of DM or treatment duration. LDL-C level was not associated with any covariate. Analysis of the subjects
divided by sex revealed a decrease in HDL-C in female subjects (during the 6~9 months period: p = 0.0054), but
not in male subjects.
Conclusions: Our study revealed that administration of candesartan slightly decreased HDL-C in female subjects.
However, TG, TC and LDL-C levels were not influenced by candesartan monotherapy. Candesartan may be safely
used for patients with hypertension with respect to lipid metabolism, because the effect of candesartan on lipids
may be small.
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Candesartan cilexetil is a selective angiotensin II type I
receptor blocker (ARB). It is known that some ARBs
improve insulin resistance [1], and we reported that
monotherapy with ARBs including candesartan had a
favorable effect on glucose metabolism [2]. Previous
clinical trials showed that candesartan-based treatment
reduced non-fatal strokes in elderly hypertensive
patients [3], and that a 7-day course of candesartan after
an acute ischaemic stroke significantly improved cardio-
vascular morbidity and mortality [4]. Pfeffer et al.
reported that administration of candesartan to patients
with chronic heart failure improved cardiovascular mor-
bidity and mortality [5]. These large-scale clinical trials
suggested the possibility that candesartan has an add-on
effect to reduce cardiovascular risk. Meanwhile, an ani-
mal study showed that candesartan increased peroxi-
some proliferator-activated receptor-g (PPAR-g)m R N A
expression and serum adiponectin level [6]. Therefore, it
has been suggested that candesartan has a potential
effect on lipid metabolism. A recent clinical study on
the effect of candesartan on lipid metabolism showed
that total cholesterol (TC) and low density lipoprotein
cholesterol (LDL-C) levels were significantly decreased
in hypertensive patients administered candesartan for at
least 6 months [7]. However, the effects of prolonged
administration of candesartan on lipid metabolism in
patients are unclear.
In this study, we carried out candesartan monotherapy
in patients, examined the longitudinal changes in plasma
lipid profile up to 12 months, and studied the correl-
ation between the profile and the duration of
administration.
Methods
Study Population
The data for this retrospective analysis were collected
from electronic medical records (EMRs) stored in the
Nihon University School of Medicine (NUSM) Clinical
Data Warehouse (CDW), which integrates clinical data
from hospital information systems (HIS) at three hospi-
tals affiliated to NUSM [2]. NUSM’sC D Wi sac o m p r e -
hensive data warehousing facility that provides data
services to users across the clinical and research sectors
of NUSM. The experimental protocol was approved by
the Ethical Committee of Nihon University School of
Medicine. The study subjects consisted of 483 Japanese
patients with mild to moderate hypertension, aged 20
years or older who had been treated initially with cande-
sartan cilexetil monotherapy (range: 1~12 mg/day, 93.5%
of administration was in the range of 2~8 mg/day) for at
least 4 weeks during the period from November 2004 to
October 2009, as shown in Figure 1. Patients who had
received antihyperlipidaemic agents were excluded from
the study. Patients who had received other antihyperten-
sive agents, such as an ARB other than candesartan,
angiotensin-converting enzyme inhibitor (ACEI), cal-
cium channel blocker, alpha-blocker, beta-blocker, alpha
+beta-blocker, alpha-agonist or thiazide, during the 3
months before candesartan cilexetil administration were
excluded from the study. In addition, patients with hae-
moglobin A1c (HbA1c) of 8.0% or higher were elimi-
nated to exclude patients with very poor glycaemic
control. Clinical data from the study subjects included
sex, age at the start of treatment, diagnosis of diabetes
mellitus (DM) according to the Committee for the Clas-
sification and Diagnosis of Diabetes Mellitus of the
Japan Diabetes Society (defined as fasting plasma glu-
cose level ≥126 mg/dl, casual plasma glucose level ≥200
mg/dl, plasma glucose 2 h after 75 g glucose load ≥200
mg/dl, or HbA1c level ≥6.5% [8]), duration of treatment,
results of blood examinations including triglyceride
(TG), TC, high density lipoprotein cholesterol (HDL-C)
and LDL-C, which were determined at routine clinical
visits, and date of examination. A total of 405 patients
from this population were eligible for the study of TG,
440 for TC, 313 for HDL-C and 304 for LDL-C.
Statistical analysis
Our main explanatory variables included sex, age at start
of treatment, diagnosis of DM, and “duration” defined as
the timing of measurement in days since the start of
treatment as follows; baseline (within 3 months before
start of treatment), 0~3 M (>0, ≤3m o n t h s ) ,3 ~ 6( > 3 ,
≤6m o n t h s ) ,6 ~ 9 M( > 6 ,≤9m o n t h s )a n d9 ~ 1 2M( > 9 ,
≤12 months). Our main response variables were
repeated measurements of TG, TC, HDL-C and LDL-C
levels in blood before and after candesartan cilexetil
monotherapy. These data were not randomized, and
were inherently unbalanced because the number and
timing of the repeated measurements were different
among individuals. The composition of the patients and
the number of examinations were not equal for each of
the treatment durations, and may have been time-
dependently affected by candesartan monotherapy itself.
Marginal structural models using inverse probability of
treatment weighting (IPTW) have been recently devel-
oped to solve this problem that the treatment effects are
affected by time-dependent confounders that are them-
selves affected by the treatment [9]. Therefore, we used
IPTW to balance the treatment durations so as to
reduce bias in the patient background and obtain a bet-
ter idea of the effect of treatment on the outcome of
compliance. IPTW is calculated as the inverse of the
propensity score. The propensity score method intro-
duced by Rosenbaum and Rubin is an effective tool to
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lanced data [10]. The traditional propensity score
method such as matching, stratification and covariance
adjustment is mostly used in binary-value treatment
[11-13]. Recently, there have been many reports trying
to expand its application to more than two treatments
[14-16]. We referred to the method introduced by Leslie
et al., and used an IPTW-linear mixed effect model to
reduce bias in the duration of treatment [15-18]. This
method consisted of three steps as follows. As the first
step, we used propensity score adjustment to account
for potential selection bias in each treatment duration.
We used a logistic regression model to calculate the
propensity score as the probability of examinations with
each treatment duration. The variables in this step
included sex, age and diagnosis of DM. As the second
step, IPTW was calculated as the inverse of the propen-
sity score. By using this IPTW in the next step, bias in
each treatment duration could be minimized. To give
more weight to smaller treatment groups, a weight was
created that reflects the sample size for each blood
examination. As the third step, an IPTW-linear mixed
effect model was fitted to analyse the relationship
between these longitudinal data of blood examinations
and all other covariates. We fitted repeated measure-
ment analysis (covariance structure: Compound Symme-
try) to the data, including sex, age, diagnosis of DM and
a confounding factor of interaction of sex and duration
of treatment as fixed effect covariates, and duration of
treatment as a repeated effect covariate. We selected the
Kenward-Roger method to compute the denominator
degrees of freedom for the tests of fixed effects. A multi-
ple-comparison test (Dunnett-Hsu post-hoc analysis)
was used to compare the differences in means between
“baseline” as a reference and other treatment duration
periods. A result was considered statistically significant
if the p value was less than 0.05. All statistical analysis
was performed with SAS 9.1.3 (SAS Institute Inc., Cary,
NC) statistical software.
Results
Characteristics of study sample
Of the study population of 483 patients with hyperten-
sion, those who had been treated with candesartan cilex-
etil monotherapy but no antihyperlipidaemic agent were
subjected to statistical analysis (Figure 1). The numbers
of blood examinations were as follows; TG: total 1114
examinations (405 patients with 2.75 measurements per
patient), TC: total 1204 examinations (440 patients with
2.74 measurements per patient), HDL-C: total 708
examinations (313 patients with 2.26 measurements per
patient), LDL-C: total 781 examinations (304 patients
with 2.57 measurements per patient) (Figure 1). Table 1
shows the details of patient information and data.
Approximately 36% of patients who underwent blood
examination were female and 64% were male. Approxi-
mately 47% of patients had DM. Mean age was approxi-
mately 61 years, and the age range was 20 to 91 years.
Relationship of covariates to plasma lipid profile
Table 2 shows the results of Type III test of propensity
score-weighted linear mixed effect models fitted to
plasma TG, TC, HDL-C and LDL-C data. There was a
significant association between HDL-C level and sex
(p = 0.0017), treatment duration (p = 0.0427), and inter-
action of sex and treatment duration (p = 0.0349), but
no association between HDL-C and age or diagnosis of
DM. There was a significant association between TG
HDL-C data 
708 examinations, 
313 patients
TC data 
1204 examinations, 
440 patients
TG data 
1114 examinations, 
405 patients
LDL-C data 
781 examinations, 
304 patients
Study 
population
Longitudinal survey 
data for 12 months
Subjects with candesartan cilexetil 
monotherapy without other antihypertensive 
agents or antihyperlipidemic agents, 
483 patients
Figure 1 Study population. Medical record reviews of longitudinal survey data were carried out for 15 months; from 3 months before to 12
months after the start of candesartan monotherapy. Detailed exclusion criteria are described in the Methods.
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and age, diagnosis of DM, treatment duration or inter-
action of sex and treatment duration. There was a sig-
nificant association between TC and sex (p = 0.0032),
but no association between TC and age, diagnosis of
DM, treatment duration or interaction of sex and treat-
ment duration. There was no association between LDL-
C and sex, age, diagnosis of DM, treatment duration or
interaction of sex and treatment duration. Candesartan
monotherapy was associated with a decrease in HDL-C
level, but had little effect on other lipid parameters.
Table 3 shows the results of Dunnett’s multiple-com-
parison test of propensity score-weighted linear mixed
effect models fitted to plasma TG, TC, HDL-C and
LDL-C data. HDL-C was slightly but significantly
decreased in the ‘6~9M’ period compared with baseline
(1.40 vs. 1.47 nmol/L, p = 0.0218), but was not signifi-
cantly changed in the other periods, ‘0~3M’, ‘3~6M’ and
‘9~12M’, compared with baseline. There was no signifi-
cant change in TG, TC or LDL-C in any treatment
duration period.
We further analysed the data divided by sex, because
HDL-C was also significantly associated with sex and
interaction of sex and treatment duration. Figure 2
shows the change in HDL-C level in each treatment
duration period, compared with baseline. HDL-C was
significantly decreased in the ‘6~9M’ period compared
with baseline in female data (1.45 vs. 1.57 nmol/L, p =
0.0054), but was not significantly changed in male data
(Figure 2 and Table 4). Candesartan monotherapy had
an unfavorable effect on HDL-C in female subjects, but
HDL-C level in female subjects was within the normal
range during the study period.
Discussion
In this study, we examined the changes in laboratory
data of lipid metabolism up to 12 months in patients
receiving candesartan monotherapy. Because this survey
was a longitudinal study, the study population repre-
sented its own time-related control group. In this retro-
spective longitudinal survey, we found a significant
reduction in HDL-C level from the start to 6~9 months
of candesartan administration (Tables 2 and 3). These
results suggest that candesartan has an unfavorable
effect on lipid metabolism, with a reduction in HDL-C
level by administration of candesartan for 6~9 months
in female subjects. However, the effect of candesartan to
reduce HDL-C level was transient and limited to female
subjects. Moreover, HDL-C level was within the normal
range throughout the study period (Table 4). Therefore,
this slightly unfavorable effect of candesartan monother-
apy on HDL-C in female subjects may not be a problem
in clinical practice. Regarding lipid metabolism, cande-
sartan may be safely used for patients with hypertension
in the long term up to 12 months. Bramlage et al.
reported that ARBs provide substantial cost savings and
may prevent cardiovascular morbidity and mortality
based on more complete antihypertensive coverage,
Table 1 Frequency distribution of blood examination
data
Variables TG TC HDL-C LDL-C
Patient information
Number of
patients
405 440 313 304
Age, years
Mean ± SE 61.2 ±
14.5
61.7 ±
14.9
60.3 ±
14.6
60.2 ±
14.4
Range 20 - 86 20 - 91 20 - 86 20 - 86
Sex, number (%)
Female 142 (35.1) 165 (37.5) 113 (36.1) 102 (33.6)
Male 263 (64.9) 275 (62.5) 200 (63.9) 202 (66.4)
DM, number (%)
No 217 (53.6) 252 (57.3) 160 (51.1) 151 (49.7)
Yes 188 (46.4) 188 (42.7) 153 (48.9) 153 (50.3)
Data information (number of examinations)
Treatment duration
Baseline 464 504 312 298
0~3M 221 262 137 156
3~6M 185 190 114 136
6~9M 136 140 84 107
9~12M 108 108 61 84
TG: triglyceride, TC: total cholesterol, HDL-C: high density lipoprotein
cholesterol, LDL-C: low density lipoprotein cholesterol, DM: diagnosis of
diabetes mellitus.
Table 2 Relationship of covariates to plasma lipid profile
Effect DF TG TC HDL-C LDL-C
F-value p value F-value p value F-value p value F-value p value
Sex 1 8.32 0.0041* 8.74 0.0032* 9.99 0.0017* 2.04 0.1539
DM 1 0 0.9978 1.42 0.2333 1.69 0.1949 0.34 0.5628
Age 1 1.79 0.1819 0.95 0.3311 0.04 0.8429 0.24 0.627
Treatment duration 4 0.4 0.812 0.68 0.6086 2.49 0.0427* 0.44 0.7812
Sex*Treatment duration 4 1.28 0.278 1.12 0.3434 2.61 0.0349* 1.82 0.1243
DM: diagnosis of diabetes mellitus, Sex*Treatment duration: interaction of sex and duration of treatment, TG: triglyceride, TC: total cholesterol, HDL-C: high
density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, DF: degrees of freedom, p value: p value of covariate, *: p < 0.05.
Nishida et al. Cardiovascular Diabetology 2010, 9:38
http://www.cardiab.com/content/9/1/38
Page 4 of 7suggesting that ARBs are an attractive choice for long-
term treatment of hypertension [19]. Our findings on
the safety of long-term use of candesartan with respect
to lipid metabolism reinforce these benefits of ARBs.
Only a few studies have examined the effect of cande-
sartan on lipid metabolism; however, some showed that
administration of candesartan had no effect on lipid
metabolism. When HDL-C, TC, and TG levels were
compared between before administration and after
2 weeks of candesartan administration to patients with
essential hypertension, no significant difference was
found [20]. Also, when HDL-C, LDL-C, TC, and TG
levels were compared between before administration
and after 8 weeks of candesartan administration to
patients with mild hypertension and type 2 DM, no sig-
nificant difference was found [21]. When HDL-C, LDL-
C, TC, and TG levels were compared between before
administration and after 12 weeks of candesartan
administration to patients with mild hypertension and
type 2 DM, no significant difference was found [22].
Furthermore, when HDL-C, LDL-C, TC, and TG levels
were compared between before administration and after
12 months of candesartan administration to patients
with mild hypertension and type 2 DM, no significant
difference was found [23]. Supporting these previous
reports, no significant changes were observed with can-
desartan administration for less than 6 months and
more than 9 months in our study.
A close relationship has been suggested between lipid
and glucose metabolism, but there was no association
between lipid metabolism and the covariate of DM in
our study results (Table 2). The reason for this may be
that only patients with well-controlled blood glucose
were selected during the subject selection stage in this
study, because patients with a very high HbA1c level
(≥8.0%) were excluded. As a result, there was a smaller
effect of glucose metabolism abnormality on lipid
metabolism.
In our study, HDL-C level was significantly reduced in
female subjects, but not in male subjects (Figure 2 and
Table 4). The reason for this discrepancy may be as fol-
lows. First, the effect of candesartan on HDL-C may be
Table 3 Multiple comparison test of levels of lipid parameters among treatment duration periods
Treatment duration TG (nmol/L) TC (nmol/L)
LS mean ± SE 95% CI p value LS mean ± SE 95% CI p value
Baseline 1.51 ± 0.05 1.42/1.61 reference 5.30 ± 0.04 5.21/5.39 reference
0~3M 1.52 ± 0.07 1.39/1.65 1 5.24 ± 0.05 5.14/5.35 0.5876
3~6M 1.53 ± 0.07 1.39/1.67 0.9984 5.30 ± 0.06 5.19/5.42 1
6~9M 1.61 ± 0.08 1.45/1.77 0.6205 5.26 ± 0.06 5.13/5.39 0.9223
9~12M 1.54 ± 0.08 1.36/1.72 0.9963 5.34 ± 0.07 5.20/5.48 0.9717
Treatment duration HDL-C (nmol/L) LDL-C (nmol/L)
LS mean ± SE 95% CI p value LS mean ± SE 95% CI p value
Baseline 1.47 ± 0.02 1.42/1.52 reference 3.12 ± 0.05 3.02/3.21 reference
0~3M 1.45 ± 0.03 1.40/1.51 0.858 3.10 ± 0.05 2.99/3.21 0.9917
3~6M 1.45 ± 0.03 1.40/1.51 0.8875 3.05 ± 0.06 2.93/3.16 0.5653
6~9M 1.40 ± 0.03 1.34/1.46 0.0218* 3.11 ± 0.06 2.98/3.23 0.9999
9~12M 1.41 ± 0.03 1.34/1.47 0.1247 3.08 ± 0.07 2.95/3.22 0.9778
TG: triglyceride, TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, LS mean: least squares mean, SE:
standard error, CI: confidence interval, p value: p value of treatment duration (compared with baseline, multiple-comparison test: Dunnett-Hsu post-hoc analysis),
*: p < 0.05.
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Figure 2 Mean change in HDL-C level in each treatment
duration period from baseline. White squares show female results
and black squares show male results. *: p < 0.05.
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those with a low HDL-C level. It is well known that
there is a sex-difference in plasma lipid profile; plasma
HDL-C level is generally higher in female subjects than
in male subjects [24,25]. Second, the effect of candesar-
tan on HDL-C may reflect its effects on hormones. A
previous report revealed that oestrogen increases HDL-
cholesterol [26]. However, the reason for this discre-
pancy between male and female subjects is still unclear.
This study was a retrospective database study, which
can provide many benefits as follows: First, real-time
data can be provided quickly and cost-effectively. Sec-
ond, the sample sizes are relatively large. Third, the
influences on the patients’ risk are minimal. These
strengths readily led to stimulating studies and promis-
ing outcomes [27]. On the other hand, our study was a
retrospective observational study, which has some lim-
itations with respect to the potential for selection bias
and confounding factors. However, these problems
caused by non-randomized data could be solved by
combination with robust statistics; for example, propen-
sity score method [9]. Our study, with appropriate appli-
cation of statistical analysis techniques; i.e., the
propensity score adjustment and weighted-linear mixed
model, may yield findings with validity, and help physi-
cians make decisions on drug selection.
Conclusions
In this study, we examined the effect of candesartan
monotherapy on lipid metabolism. Our results revealed
that HDL-C level in female subjects declined from 6 to
9 months after the initiation of candesartan monother-
apy. However, the reduction of HDL-C level was transi-
ent and was observed only in female subjects. Moreover,
the HDL-C level was within the normal range through-
out the study period. In addition, TG, TC and LDL-C
levels were not influenced by candesartan monotherapy.
These results indicate a lack of obvious evidence show-
ing an unfavorable influence of candesartan on lipid
metabolism. Therefore, the influence of candesartan
monotherapy on lipid metabolism may be small and
m a yn o tb eac l i n i c a lp r o b l e m .I nt h ef i e l do fl i p i d
metabolism, candesartan may be safely used for patients
with hypertension.
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